StepStone's fertility CV prices equity like credit

StepStone is leading a continuation vehicle for US Fertility, and the number that leads the public outline is a count of families rather than a price; no valuation is attached to the deal. Set beside Pantheon's €1.2bn continuation of Bridgepoint Credit, which closed earlier in September with no public benchmark of its own, the two look like one phenomenon repeating, and the difference is where the GP-led market is being pushed.

A rolling LP gets a healthcare story and, presumably, the sponsor's model; what it does not get is a mark that can be checked against the last comparable deal, the ordinary currency of argument in private equity, and so the buyers weighing the rollover are underwriting one lead buyer's confidence in a number the sponsor produced, at terms the coverage does not describe.

A missing price matters more here than in most corners of the market, because a continuation vehicle exists to give an LP a real alternative to holding to the end of a fund's life, and the price is the whole substance of that alternative. An LP that rolls at a number the market never sees has still made a decision, but not one an outsider can check, and the cost of that lands on the LPs with the least leverage to insist otherwise.

There is a defensible version of the blank, and the credit market has been living in it: no public comparables exist for a private credit portfolio, so the €1.2bn Bridgepoint Credit vehicle priced off covenants, rollover terms and the lead buyer's underwriting instead. That is a sound answer to a question with no published answer, and it required nobody to take a sponsor's word for an absence.

A fertility network is a business where a buyer can assemble comparables — public operators, recent transactions, the kind of work a deal team does in a week — which is what makes the blank read as a preference rather than a constraint. The likelier reading is that the sponsor's mark is the anchor, that the negotiation runs between the sponsor and the lead buyer of record, and that rollovers are offered at terms the rolling LPs had no hand in setting.

HarbourVest's buyout index turned negative, and that does more work than it appears to: while the benchmark was rising, a price at or near the mark had a factual ring to it, but with it falling the same claim becomes a negotiating position. The gap between what a sponsor says an asset is worth and what a buyer will pay stops being something an outsider can read off a chart, and the deal's terms become the only text available; a negative print forces nobody to price lower, but it removes the cover a rising market gave both sides of the table.

Kelso's $510m MEP continuation vehicle closed the same day as Pantheon's credit deal, and the coverage described both as pricing on terms rather than marks, with the Kelso vehicle the unremarkable one of the pair. TrueBridge closed a $508m secondaries fund into a market that has come apart along a clean line, with venture buyers taking discounts and GP-led sellers getting the sponsor's number, while single-asset vehicles for a fitness-equipment maker and a shipping franchise cleared and the mega LP portfolios waited.

Two pricing mechanisms are now running side by side, and the difference between them is who does the work: when a comparable exists, buyer and seller argue against something external and the outcome can be checked afterwards. Where none exists, the lead buyer's underwriting is the price, and the rest of the syndicate takes it or leaves the rollover. The LP-led buyer starts from a discount to the sponsor's mark; the GP-led buyer starts from the mark itself, same underlying assets, two different arguments, and only one buyer has to explain the arithmetic to anyone.

The clearest measure of how far the second mechanism has travelled is that it no longer arrives with an excuse: private credit's lack of listed comparables explained its blank, but a services platform with deal comps in circulation has no equivalent excuse, and the market is not requiring one. That is how a pricing convention becomes a pricing standard in everything but name.

Speed favors the second mechanism, and so does the sponsor, which is why the flow is where it is; the real constraint all along has been the supply of deals that can be structured as a single asset, priced without a reference point and cleared by a short list of LPs whose alternative is to wait years for a fund to wind itself down.

The fertility deal is not the first of its shape for the lead buyer: Gainline Capital Partners rolled Core Health & Fitness, a fitness-equipment maker, into a StepStone-led continuation vehicle, so the firm now has two single-asset consumer deals, both led by StepStone and neither arriving with a public price signal. Two examples do not make a franchise, but the shape is consistent enough to name — StepStone appears to be building a position in sponsor-owned businesses where the pricing has to come from a buyer rather than from the tape, and where it is consequently well placed to be the buyer of record.

That position pays while the market holds: a lead buyer on an unbenchmarked single asset sets the price it will pay and the terms it will accept, collects on both, and does so without publishing a number a rival can undercut. The failure mode has a long fuse — if one of these assets has to be marked down before an exit, the argument moves to what the sponsor's model said at the time of the rollover, because there is no public print for a rolling LP to point at. Nothing in the week's activity suggests trouble is coming, but it does show where the accountability sits when a price is never published: with the lead buyer and the LPs who chose to stay.

The supply side of the same story is InXpress: Hudson Hill closed a single-asset continuation vehicle for the company, and the week's coverage placed that deal alongside the fitness-equipment maker as the unglamorous end of the market clearing while large portfolios wait. For sponsors, the appeal of the format is as much the number of counterparties as the price, since a single-asset vehicle concentrates diligence, negotiation and consent into a handful of LPs, which likely keeps the process quieter than a strip of a dozen companies would be.

The rollover is the least examined and highest-consequence decision in the structure: an LP that stays in a continuation vehicle is not voting on the sector story but on one sponsor's projections and one lead buyer's underwriting at a price neither of them published. In the credit deals, the things being negotiated — covenants, rollover provisions — are at least the subject of the terms and can be read by the people signing them, while in a single-asset services equity deal the terms are the price, and the price is quiet.

The register of disclosure is instructive on its own: the US Fertility coverage led with a count of families, a marketing number, and sponsors who lead with marketing numbers are addressing a wider audience than the small group of LPs deciding whether to stay. There is nothing improper in that as salesmanship, but it does mean the published outline of a benchmark-free deal carries almost no economic content, because the one number a reader could use is the one that was left out.

Golub Capital committed $1bn to secondaries and TrueBridge's fund closed at $508m, so the money is plainly there; on the evidence of this week it goes into single assets that clear without a benchmark, which makes the shortage of those deals the binding constraint and gives the sponsors running them the upper hand on every term that matters. A buyer with $1bn to place and a shortage of inventory is not a hard negotiator.

The next single-asset services vehicle StepStone leads will show whether the US Fertility blank was a choice about one deal or the format for the franchise behind it. Until one of these vehicles carries a published price, the family count remains the one number the outline offers.